Fate Therapeutics again amends IPO

Stem cell company Fate Therapeutics Inc. (San Diego, Calif.) again amended its IPO and now plans to sell 6.7 million shares at $6-$8. At the $7 midpoint, the company would raise $46.7 million and be valued at $133.4 million. Earlier this month, Fate said it planned to sell 4 million shares at $14-$16. At the $15 midpoint, the company would have raised $60 million and been valued at $218.7 million. Fate filed to raise up to $69 million in the IPO last month. Cowen; BMO Capital Markets; and Wedbush are underwriters. ...